FDA Approves Dato-DXd in HR+/HER2– Breast Cancer
As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for patients with HR-positive, HER2-negative breast cancer.
Related Articles
High Immunoglobulin Expression Shows Long-Term Survival in Breast Cancer
Data support the IGG signature, especially its key gene subset, as a potential marker of sustained antitumor activity in breast cancer.
Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy
Using immunotherapeutic agents like inotuzumab ozogamicin (InO), blinatumomab, or chimeric antigen receptor T (CAR T)-cell therapy in frontline adult B-cell acute lymphoblastic leukemia (B-ALL) the…
Robotic Right Hepatectomy following Portal Vein Embolization for Colorectal Liver Metastases
This video is a robotic right hepatectomy for multifocal/bilateral colorectal liver metastases. The left-sided lesions were previously treated. The video inc…
Over 18 000 doctors urge Senate to reject Robert F Kennedy Jr as health secretary
More than 18 000 US doctors have signed a letter calling on the Senate to reject Robert F Kennedy Jr as the federal secretary of…
Estonian government bans tattoos, tanning for teens
Tallinn [Estonia], November 11 (ANI/Sputnik): The Estonian government approved on Thursday a draft law on public health, which, among other items, will ban tattoos and…
Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review
Inotuzumab ozogamicin (InO) is indicated for the treatment of adults with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL). This systematic literature review (CRD42022330496) assesse…
Fellow – American Society for Radiation Oncology (ASTRO) – American Society for Radiation Oncology (ASTRO)
The ASTRO Fellow designation (FASTRO) is awarded based on length of ASTRO membership and commendable service to ASTRO and to the field of radiation oncology.
What Clinicians Want to Know: Biomarker Assessment and Related Treatment Decision-Making for Patients with Colorectal Cancer — Friday, January 24, 2025, San Francisco | Research To Practice
Friday, January 24, 2025, San Francisco, California, 6:00 PM – 8:00 PM Pacific Time (9:00 PM – 11:00 PM Eastern Time) Location San Francisco Marriott…
Meta ends fact-checking, drawing praise from Trump
Meta CEO Mark Zuckerberg ended fact-checking on Facebook and Instagram in favor of community notes, calling the recent election a “cultural tipping point” on free…
